Clinical trials: Hidradenitis, open to volunteers
Hidradenitis Suppurativa (HS)
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe…
- Trial name
- NCT07489573
- Testing
- Secukinumab
- Where
- 10 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
The Safety and Efficacy of Roflumilast Foam in HS
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- NCT07263230
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT)
FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge.
- Trial name
- FESTIVAL (NCT07668713)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- 7 sites in France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa
Pathophysiological Basis of Hidradenitis Suppurativa
HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous…
- Trial name
- NCT06370052
- Testing
- excision
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Center Rijeka
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Inflammatory Bowel Diseases, Ulcerative Colitis
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid
- Trial name
- MISTIC (NCT04191395)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hidradenitis Suppurativa (HS)
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin.
- Trial name
- WMCREI (NCT07155239)
- Testing
- AviClear Lase Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wynn Medical Center
Hidradenitis Suppurativa
Clinical and Biological Characteristics of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition.
- Trial name
- NCT03967600
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in…
- Conditions
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
- Trial name
- NCT06926192
- Testing
- Surgery combined with secukinumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College
Hidradenitis Suppurativa (HS)
MAIT Cells in Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a chronic, debilitating inflammatory skin disease characterized by painful, purulent lesions primarily in skin folds. Its pathogenesis remains poorly understood.
- Trial name
- HS-MAIT (NCT07388446)
- Testing
- Collect lesional biopsies, Collect score from Bristol stool scale
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa
- Trial name
- NCT07828860
- Testing
- Soquelitinib
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Hidradenitis Suppurativa
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
The purpose of this protocol is to examine the cytokine profi le of pati ents with hidradeniti s suppurati va (HS) and idemechanisms responsible for post-transcripti onal regulati on of these genes.
- Trial name
- NCT05507125
- Testing
- Mental health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Hidradenitis Suppurativa (HS)
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
The goal of this clinical trial is to learn if combining an IL-17A/F monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS).
- Trial name
- NCT07554014
- Testing
- IL-17A/F mAb + NAFL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hidradenitis Suppurativa
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
The goal of this clinical trial is to compare the efficacy secukimumab versus tofacitinib in patients with moderate to severe hidradenitis suppurativa (HS)in adults.
- Trial name
- NCT06707246
- Testing
- Secukinumab 300 MG; Tofacitinib 11mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hidradenitis Suppurativa (HS)
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS.
- Trial name
- Mainsail (NCT07384975)
- Testing
- NAV-240
- Where
- 41 sites in United States, Bulgaria and 6 more
- Volunteers
- 150 people
- Sponsor
- Navigator Medicines, Inc.
Hidradenitis Suppurativa
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
- Trial name
- ABCESS2 (NCT05821478)
- Where
- 4 sites in France
- Volunteers
- 92 people
- Sponsor
- Institut Pasteur
Hidradenitis Suppurativa
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.
- Trial name
- NCT07007637
- Testing
- Sonelokimab
- Where
- 166 sites in United States, Belgium and 14 more
- Volunteers
- 835 people
- Sponsor
- MoonLake Immunotherapeutics AG